Latest Insider Transactions at Regulus Therapeutics Inc. (RGLS)
This section provides a real-time view of insider transactions for Regulus Therapeutics Inc. (RGLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Regulus Therapeutics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Regulus Therapeutics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 25
2024
|
Kathryn J Collier |
BUY
Open market or private purchase
|
Direct |
4,000
+37.24%
|
$4,000
$1.82 P/Share
|
|
Mar 14
2024
|
Stelios Papadopoulos |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+20.35%
|
$250,000
$1.6 P/Share
|
|
Jan 18
2024
|
Joseph P Hagan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,580
-20.34%
|
$14,580
$1.19 P/Share
|
|
Jan 18
2024
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Open market or private sale
|
Direct |
5,468
-35.22%
|
$5,468
$1.19 P/Share
|
|
Jan 18
2024
|
Crispina Calsada Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,468
-48.6%
|
$5,468
$1.19 P/Share
|
|
Jan 12
2024
|
Joseph P Hagan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+29.5%
|
-
|
|
Jan 12
2024
|
Christopher Ray Aker Sr. VP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+42.02%
|
-
|
|
Jan 12
2024
|
Crispina Calsada Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+50.0%
|
-
|
|
Apr 13
2023
|
Stelios Papadopoulos |
BUY
Grant, award, or other acquisition
|
Direct |
222,198
+23.37%
|
$0
$0.9 P/Share
|
|
Mar 01
2022
|
Denis Drygin Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
76,686
+43.4%
|
$0
$0.23 P/Share
|
|
Feb 04
2022
|
Denis Drygin Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
23,314
+50.0%
|
$0
$0.23 P/Share
|
|
Jan 26
2022
|
Joseph P Hagan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+19.34%
|
$0
$0.22 P/Share
|
|
Nov 30
2021
|
Stelios Papadopoulos |
BUY
Grant, award, or other acquisition
|
Direct |
2,222,222
+30.51%
|
$0
$0.36 P/Share
|
|
May 17
2021
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Open market or private sale
|
Direct |
860
-2.02%
|
$0
$0.89 P/Share
|
|
May 17
2021
|
Joseph P Hagan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,186
-1.31%
|
$0
$0.89 P/Share
|
|
Apr 14
2021
|
Joseph P Hagan Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
75,850
+19.14%
|
-
|
|
Feb 16
2021
|
Joseph P Hagan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,144
-0.85%
|
$4,144
$1.72 P/Share
|
|
Feb 16
2021
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Open market or private sale
|
Direct |
828
-1.91%
|
$828
$1.72 P/Share
|
|
Dec 04
2020
|
Stelios Papadopoulos |
BUY
Grant, award, or other acquisition
|
Direct |
793,528
+28.54%
|
$0
$0.63 P/Share
|
|
Dec 04
2020
|
Joseph P Hagan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
39,680
+14.95%
|
$0
$0.63 P/Share
|
|
Dec 04
2020
|
Growth Equity Opportunities V, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
4,398,602
+40.54%
|
$0
$0.62 P/Share
|
|
Dec 04
2020
|
Forest Baskett > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,398,602
+40.54%
|
$0
$0.62 P/Share
|
|
Dec 04
2020
|
Ali Behbahani > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,398,602
+40.54%
|
$0
$0.62 P/Share
|
|
Dec 04
2020
|
Carmen Chang > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,398,602
+40.54%
|
$0
$0.62 P/Share
|
|
Dec 04
2020
|
Anthony A. Florence Jr. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,398,602
+40.54%
|
$0
$0.62 P/Share
|
|
Dec 04
2020
|
Mohamad Makhzoumi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,398,602
+40.54%
|
$0
$0.62 P/Share
|
|
Dec 04
2020
|
Joshua Makower > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,398,602
+40.54%
|
$0
$0.62 P/Share
|
|
Dec 04
2020
|
Scott D Sandell > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,398,602
+40.54%
|
$0
$0.62 P/Share
|
|
Dec 04
2020
|
Peter W. Sonsini > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,398,602
+40.54%
|
$0
$0.62 P/Share
|
|
Dec 04
2020
|
Paul Edward Walker > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,398,602
+40.54%
|
$0
$0.62 P/Share
|
|
Nov 16
2020
|
Joseph P Hagan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,094
-2.74%
|
$0
$0.52 P/Share
|
|
Nov 16
2020
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Open market or private sale
|
Direct |
876
-3.29%
|
$0
$0.52 P/Share
|
|
Nov 12
2014
|
Astrazeneca PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,000,000
-32.0%
|
$34,000,000
$17.0 P/Share
|
|
Feb 04
2014
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,303,780
+20.51%
|
$9,126,460
$7.67 P/Share
|